HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.
HiFiBiO Therapeutics has operations in Paris, France, Cambridge, MA, USA and Hangzhou, China.
HiFiBiO Therapeutics has operations in Paris, France, Cambridge, MA, USA and Hangzhou, China.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $179.5M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | B Capital ... | b.capital/ |
| - | B Capital ... | bcapgroup.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 22.06.2021 | Series D | $75M | IDG Capita... |
| 29.08.2019 | Series C | $67M | - |
| 18.05.2018 | Series B | $37.5M | - |
Mentions in press and media 21
| Date | Title | Description |
| 09.01.2023 | HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603 | HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603. HFB200603 is a novel mon... |
| 15.06.2021 | HiFiBiO Therapeutics secures $75M | HiFiBiO Therapeutics has raised $75 million in a Series D led by Mirae Asset Financial Group. Founded in 2013, the company is a developer of single-cell profiling technologies designed to accelerate biotherapeutics that combat cancer and au... |
| 15.06.2021 | SoftBank Vision Fund 2 builds momentum | IRL, a Gen-Z-focused messaging app maker with just 25 employees, became a unicorn on Tuesday. It’s an enormous valuation for a company with so few workers. But IRL’s attainment of unicorn status had been anticipated for a while. New social ... |
| 15.06.2021 | China’s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group | HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean gl... |
| 15.06.2021 | China’s HiFiBiO Therapeutics bags $75m Series D led by Mirae Asset Financial Group | Premium HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a K... |
| 15.06.2021 | SoftBank ramps up its unicorn bets in 2021, taking a social media company to $1 billion | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. IRL, a Gen-Z-focused messaging app maker with just 25 employees, became a unicorn on Tuesday. It’... |
| 14.06.2021 | HiFiBiO Therapeutics Closes $75M Series D | CAMBRIDGE, MA, HiFiBiO Therapeutics announced the completion of an oversubscribed $75M Series D financing round led by Mirae Asset Financial Group. >> Click here for more funding data on HiFiBiO Therapeutics >> To export HiF... |
| 14.06.2021 | HiFiBiO Therapeutics : Closes $75 Million Series D Financing to Accelerate Pipeline With Two Lead Immuno-Oncology Programs and Validate Its DIS™ Approach in the Clinic | HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and drug intelligent science, today announced the completion of an oversubscribed $75M Series D financing round. The funding was led by t... |
| 14.06.2021 | HiFiBiO Therapeutics Closes $75M Series D Financing | HiFiBiO Therapeutics, a Cambridge, Massachusetts-based multinational biotechnology company with expertise in immune modulation and drug intelligent science, closed a $75M Series D financing round. The round was led by the new investor Mirae... |
| 29.08.2019 | IDG Capital leads $67m Series C in biotech firm HiFiBio Therapeutics | Premium HiFiBio Therapeutics, an emerging multinational biotherapeutics company based in France, has raised $67 million in its Series C funding round led by new investor IDG Capital with participation from existing shareholder Sequoia Capit... |
Show more